TBX-3400 is under clinical development by Taiga Biotechnologies and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TBX-3400’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TBX-3400 overview

TBX-3400 is under development for the treatment of relapsed or refractory metastatic melanoma, solid tumors, HBV associated hepatocellular carcinoma, hepatitis B, human papillomavirus infections and infectious diseases. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex-vivo with fusion protein (TBX-4000 (Tat-MYC)). The therapeutic candidate is administered as intravenous infusion.

Taiga Biotechnologies overview

Taiga Biotechnologies (Taiga Biotech) is a biopharmaceutical company that develops protein and cellular therapies. The company develops therapies for diseases including cancers and infectious diseases. It provides pipeline products such as programs such as stem cell therapy and targets specific T-cells, among others. Taiga Biotech provides programs are developed for diseases such as HIV and influenza, and hematologic conditions. The company provides technologies for HSCs that offers variety of applications for drug discovery, screening, product development, and others. It conducts research in the clinical areas of red blood cell pharming, vaccine adjuvants cell therapies, bone marrow engraftment enhancer, and others. The company utilizes natural defenses to fight infectious disease and various forms of cancer, including both hematological cancers, solid tumors, and others. Taiga Biotech is headquartered in Aurora, Colorado, the US.

For a complete picture of TBX-3400’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.